# Tirzepatide vs Retatrutide: Key Differences at a Glance

**By TelosRX Editorial Team** · 2026-09-24

**Tirzepatide and retatrutide both target GLP-1 pathways for weight loss, but retatrutide adds a third hormone receptor — glucagon — creating meaningful differences in mechanism, evidence, and who each medication may suit best. [TelosRX](https://telosrx.com) breaks down what the research actually shows.**

Tirzepatide is FDA-approved and widely available. Retatrutide is investigational — not FDA-approved — but has generated some of the highest weight-loss percentages reported in clinical trials to date. The core difference between them is a single added receptor pathway.

Here's what that difference means in practice.

## Tirzepatide vs Retatrutide: Key Differences at a Glance

Feature

Tirzepatide

Retatrutide

**Mechanism**

Dual agonist (GLP-1 + GIP receptors)

Triple agonist (GLP-1 + GIP + Glucagon receptors)

**FDA Status**

Approved (Zepbound / Mounjaro)

Investigational — not FDA-approved

**Mean weight loss (highest dose)**

Up to 20.9–22.5% at 72 weeks (Phase 3)

Up to 24.2% at 48 weeks (Phase 2); 28.7% at 68 weeks (Phase 3 interim)

**Liver fat reduction**

Significant improvement in most trials

Up to 85% hepatic steatosis resolution in Phase 2 subset data

**Heart rate effect**

Mild, transient

Dose-dependent increase peaking ~week 24, then declining

**Administration**

Once-weekly subcutaneous injection

Once-weekly subcutaneous injection (in trials)

**Compounded availability**

Available subject to medical approval by a licensed provider

Compounded retatrutide is not FDA-approved; subject to provider evaluation

**Evidence base**

Phase 3 complete; 3-year extension data available

Phase 3 ongoing (TRIUMPH program); results expected late 2026

These weight-loss figures come from separate studies with different patient populations and timelines. A direct head-to-head trial (TRIUMPH-5) is ongoing, with results expected December 2026.

## How Each Medication Works

### Tirzepatide: Dual-Receptor Action

Tirzepatide binds both GLP-1 and GIP receptors simultaneously. GLP-1 (glucagon-like peptide-1) slows gastric emptying, reduces appetite, and stimulates insulin secretion in response to meals. GIP (glucose-dependent insulinotropic polypeptide) adds synergistic effects on fat storage regulation and energy metabolism.

The dual mechanism produced impressive results in the SURMOUNT-1 Phase 3 trial: mean weight reduction up to 20.9% at 72 weeks at the 15mg dose, with more than 60% of participants achieving 20%+ body weight loss. The FDA approved tirzepatide for chronic weight management (as Zepbound) and type 2 diabetes (as Mounjaro).

### Retatrutide: Triple-Receptor Action

Retatrutide retains everything tirzepatide does, then adds glucagon receptor agonism. The glucagon component adds two meaningful effects: it increases energy expenditure at rest (your body burns more calories passively), and it targets hepatic fat directly.

In its NEJM-published [Phase 2 obesity trial](https://pubmed.ncbi.nlm.nih.gov/37366315/), participants on the 12mg dose achieved a mean 24.2% weight reduction at 48 weeks — and hadn't yet plateaued when the study ended. Eli Lilly announced Phase 3 TRIUMPH-4 interim results in December 2025: up to 28.7% mean weight loss at 68 weeks in patients with obesity and knee osteoarthritis.

These numbers are striking. But retatrutide is not FDA-approved, and Phase 3 data is still being published. The SURMOUNT-1 tirzepatide trial ran 72 weeks; the retatrutide 28.7% comes from a different patient population at 68 weeks. Direct comparison of percentages across different studies is not scientifically sound without controlling for those differences.

## Side Effects: What Differs Between the Two

Both share the incretin-class GI side effect profile: nausea, diarrhea, constipation, and vomiting. These are dose-dependent and typically peak during the titration phase, then diminish with consistent dosing. They are not unique to either drug.

The meaningful differential for retatrutide is **a transient, dose-dependent heart rate increase**. In Phase 2 data, heart rate increases were observed, peaked around week 24, and then declined toward baseline. This makes cardiovascular screening especially important in a retatrutide evaluation.

-   **Tirzepatide:** well-characterized safety profile from Phase 3 data and real-world clinical use
-   **Retatrutide:** GI side effects comparable; adds the heart rate signal; long-term safety profile still being established in ongoing Phase 3
-   **Both:** carry the class warning for GLP-1 receptor agonists regarding medullary thyroid carcinoma (personal or family history is a contraindication to consider)

## Efficacy Beyond Weight: Liver and Metabolic Markers

Weight loss percentages are the headline, but metabolic outcomes tell the fuller story.

**Tirzepatide:** SURMOUNT-1 showed a 94% reduction in progression from pre-diabetes to type 2 diabetes over three years. Cardiometabolic markers (blood pressure, fasting glucose, triglycerides) improved substantially. DXSA body composition data showed approximately 75% of weight lost came from fat mass and 25% from lean mass.

**Retatrutide:** Phase 2 data showed strong improvements in cardiometabolic markers. The liver data is notable: in a subset analysis, retatrutide led to resolution of hepatic steatosis (fatty liver) in roughly 85% of participants at higher doses. The glucagon receptor component appears to drive this directly — an advantage over dual agonists for patients with significant liver fat involvement.

For more on muscle preservation during GLP-1 therapy, see our guide on [muscle loss and lean mass on GLP-1 medications](https://www.telosrx.com/blogs/glp1/muscle-loss-on-semaglutide-lean-mass-glp1). Strategies discussed there — protein intake, resistance training, and potential peptide support — apply to both tirzepatide and retatrutide protocols.

## Who Might Consider Tirzepatide

Tirzepatide is the better-characterized option with full Phase 3 data and FDA approval. It's the established choice for most people starting a GLP-1 program.

-   Patients prioritizing proven Phase 3 evidence and real-world safety data
-   Those with pre-diabetes or elevated blood glucose who want strong glycemic improvement alongside weight management
-   Anyone who wants the lower-cost compounded option with the most clinical experience behind it

Compounded tirzepatide is available through TelosRX's asynchronous evaluation process — **subject to medical approval by a licensed provider**. Our guide to [compounded tirzepatide via telehealth](https://www.telosrx.com/blogs/glp1/compounded-tirzepatide-telehealth-2026) covers the process in detail.

Start your private evaluation at [TelosRX](https://telosrx.com) to explore your options.

## Who Might Consider Retatrutide

Retatrutide's additional glucagon receptor pathway may offer advantages in specific metabolic situations. The evidence is compelling but still Phase 3-incomplete.

-   Patients with significant hepatic steatosis (fatty liver): the glucagon component appears potently active on liver fat
-   Those who plateaued on a GLP-1 or dual agonist at optimal dosing and are considering the next tier of efficacy
-   Patients for whom the additional energy expenditure effect of glucagon agonism is clinically relevant — particularly in cases of metabolic syndrome with a sluggish metabolic rate

Because retatrutide is not FDA-approved, compounded retatrutide is also not FDA-approved. Access requires **evaluation and approval by a licensed provider** through an asynchronous process. No real-time call is required at TelosRX — your evaluation is reviewed at your pace.

## Cost and Access: The Practical Picture

Tirzepatide (Zepbound) carries a high brand-name list price. Compounded tirzepatide is significantly more affordable for eligible patients and is available now, **subject to provider approval** following an asynchronous telehealth evaluation.

Retatrutide is not commercially available. It is available through clinical trials and — for eligible patients subject to provider evaluation — through compounding pharmacies operating under federal compounding regulations. Eli Lilly's regulatory submission is anticipated following Phase 3 completion.

TelosRX operates as an online-first, asynchronous telehealth service. No in-person visits. No scheduled phone calls. Your evaluation is reviewed by a licensed provider at a time that suits you.

## Frequently Asked Questions

### Is retatrutide better than tirzepatide?

Retatrutide has shown higher mean weight-loss percentages in clinical trials to date. But these are separate studies — not a direct head-to-head comparison. Tirzepatide has significantly more Phase 3 data and real-world experience. Which is "better" depends entirely on your specific health profile, goals, and the provider's evaluation of your case.

### Is retatrutide FDA-approved?

No. As of September 2026, retatrutide is investigational. Eli Lilly's TRIUMPH Phase 3 program is ongoing, and an FDA submission is anticipated following program completion. Compounded retatrutide is also not FDA-approved.

### What is the difference between dual and triple agonism?

Tirzepatide activates GLP-1 and GIP receptors. Retatrutide activates those two plus the glucagon receptor. The added glucagon pathway is studied primarily for increased resting energy expenditure and direct liver fat reduction — effects tirzepatide produces less directly.

### Can I get compounded tirzepatide or retatrutide through telehealth?

Compounded versions of both are prepared under federal compounding regulations and are not FDA-approved. Access requires evaluation and approval by a licensed provider through an asynchronous telehealth evaluation. TelosRX facilitates this fully online, with no live calls required.

### What are the main side effects of retatrutide vs tirzepatide?

Both cause GI side effects (nausea, diarrhea, constipation) that are dose-related and typically improve during titration. Retatrutide additionally showed dose-dependent heart rate increases in Phase 2, peaking around week 24. Cardiovascular screening is especially important with retatrutide evaluation.

### How much weight loss does tirzepatide produce?

In the SURMOUNT-1 Phase 3 trial, participants at the 15mg dose achieved a mean 20.9–22.5% weight reduction at 72 weeks. Individual results vary significantly and depend on adherence, lifestyle, and baseline health factors. Results are subject to provider evaluation and approval.

### What does retatrutide do for the liver?

In Phase 2 data, retatrutide led to resolution of hepatic steatosis in roughly 85% of participants at higher doses in a subset analysis. The glucagon receptor component drives this liver-specific effect — making retatrutide a particularly interesting option for patients with fatty liver, pending FDA approval.

### Does retatrutide have more side effects than tirzepatide?

Core GI side effects are similar between both. Retatrutide adds a transient heart rate increase not seen as prominently with tirzepatide. Long-term safety data for retatrutide is still being collected in ongoing Phase 3 trials, so the full picture isn't yet finalized.

_TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._

Start your private evaluation at [TelosRX](https://telosrx.com).

**Tags:** compounded peptides, GLP-1, obesity treatment, retatrutide, tirzepatide, triple agonist, weight loss

---

> Source: [Telos RX](https://www.telosrx.com/blogs/glp1/tirzepatide-vs-retatrutide-comparison)